CAR T-Cell Therapy: Delving Into Evolving Topics, Critical Aspects of Management, and Practice-Changing Data

Engage with this series of 6 ClinicalThought expert commentaries designed to keep you up to date over time with the latest findings in CAR T-cell therapy. A downloadable slideset based on the commentaries will help apply the education in the clinic or in your own presentations.
Alix Beaupierre, BSN, RN, OCN
Michael R. Bishop, MD
Matthew J. Frigault, MD
person default
Caron A. Jacobson, MD
Shilpa Paul Headshot
Shilpa Paul, PharmD, BCOP
Noopur Raje, MD

ClinicalThought

Are you aware of the latest data on CAR T-cell therapy in myeloma and the implications for our patients? Read my thoughts on this emerging treatment strategy and how I am using these agents in my practice.

Noopur Raje, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: August 16, 2019 Expired: August 15, 2020

What do you tell your patients who are about to receive CAR T-cell treatment? Here are the things I talk about when counseling these patients.

Alix Beaupierre, BSN, RN, OCN Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 9, 2019 Expired: September 8, 2020

New clinical data are emerging on combining CAR T-cell therapy with checkpoint inhibitors. Here’s my take on the potential of this strategy to improve outcomes in patients who relapsed or never responded to CAR T-cell monotherapy.

person default Caron A. Jacobson, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 10, 2019 Expired: September 9, 2020

A multidisciplinary team approach is vital to managing acute and long-term toxicities related to CAR T-cell therapy. Read my thoughts on the important roles of clinical and staff pharmacists in toxicity prevention, identification, and care for patients receiving these cutting-edge cellular therapies.

Shilpa Paul Headshot Shilpa Paul, PharmD, BCOP Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: February 17, 2020 Expired: February 16, 2021

CAR T-cell therapy was one of the hottest topics at the 2019 ASH annual meeting. In this commentary, Michael R. Bishop, MD, provides his thoughts on key studies on this topic from the meeting.

Michael R. Bishop, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: January 31, 2020 Expired: January 30, 2021

Emerging data and clinical experience support offering CAR T-cell therapies to patients who would have been ineligible for registrational trials. How can we optimize our real-world patients to experience the best outcomes with these potentially curative therapies?

Matthew J. Frigault, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: March 4, 2020 Expired: March 3, 2021

Downloadable Slideset

Review expert insights on incorporating CAR T-cell therapies into management of hematologic malignancies, including optimization of real-world patients, multidisciplinary management of toxicities, patient and caregiver education, and emerging data on the most promising investigational strategies.

Matthew J. Frigault, MD Released: March 24, 2020
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Celgene Corporation
Gilead Sciences

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?